Apixaban for the Acute Treatment of Venous Thromboembolism in Children

  • End date
    Apr 30, 2023
  • participants needed
  • sponsor
Updated on 28 July 2022
vitamin k antagonist
vitamin k
venous thromboembolism
anticoagulation therapy


To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

Condition Venous Thromboembolism
Treatment Standard of Care, Apixaban
Clinical Study IdentifierNCT02464969
Last Modified on28 July 2022


Yes No Not Sure

Inclusion Criteria

Birth to <18 years of age with a minimum weight of 2.6 kg at the time of randomization
Presence of an index VTE which is confirmed by imaging
Intention to manage the index VTE with anticoagulation treatment for at least 6 to 12 weeks
Subjects able to tolerate oral feeding, nasogastric (NG), gastric (G) feeding and are currently tolerating enteric medications, as per investigator's judgement

Exclusion Criteria

Anticoagulant treatment for the index VTE for greater than 14 days prior to randomization. Neonates that are enrolled into the PK cohort must be on a minimum of 5 days and a maximum of 14 days SOC anticoagulation prior to randomization. Neonates that are enrolled into the post PK cohort may receive SOC anticoagulation for up to 14 days prior to randomization
Thrombectomy, thrombolytic therapy, or insertion of a caval filter to treat the index VTE
A mechanical heart valve
Active bleeding or high risk of bleeding at the time of randomization
Intracranial bleed, including intraventricular hemorrhage, within 3 months prior to randomization
Abnormal baseline liver function at randomization
Inadequate renal function at the time of randomization
Platelet count <50×109 per L at randomization
Uncontrolled severe hypertension at the time of randomization
Use of prohibited concomitant medication at the time of randomization
Female subjects who are either pregnant or breastfeeding a child
Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment
Unable to take oral or enteric medication via the NG or G tube
Known inherited or acquired antiphospholipid syndrome (APS)
Known inherited bleeding disorder or coagulopathy with increased bleeding risk (eg, hemophilia, von Willebrand disease, etc.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note